Frazier Lifesciences Acquisition announced today that its shareholders voted in favor of the proposed business combination with NewAmsterdam Pharma Holding B.V., a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases.
More than 90% of the votes cast were in favor of the deal, the SPAC said in a press release. Share redemptions reached about 32% of the outstanding stock. That would leave about $94 million out of the $138 million Frazier raised in a December 2020 IPO.
The deal has further support from an upsized PIPE of approximately $235 million.
At announcement in July, the transaction had an enterprise value of $326 million.
The business combination is expected to close Nov. 22. Read more.
